Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness.
Shekelle
P
P
Morton
S
S
Atkinson
S
S
Suttorp
M
M
Tu
W
W
Heidenreich
P
P
Gubens
M
M
Maglione
M
M
Jungvig
L
L
Roth
E
E
Newberry
S
S
D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use*; D044383:Black People / Q000706:statistics & numerical data*; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D008297:Male; D013599:Systole; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000191:economics
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors